OBJECTIVE—To examine the mechanisms of action, therapeutic potential, and challenges
inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the …

Although there is abundant evidence that hyperglucagonaemia plays a key role in the
development of hyperglycaemia in type 2 diabetes, efforts to understand and correct this …

The effects of different iv doses of glucagon-like peptide 1 (GLP-1) on glucose homeostasis
and gastric emptying were compared in patients with type 2 diabetes. Twelve patients with …

OBJECTIVE—To assess the 12-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor
LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment …

Context: First-phase insulin secretion (within 10 min after a sudden rise in plasma glucose)
is reduced in type 2 diabetes mellitus (DM2). The incretin mimetic exenatide has …

Abstract Aims Glucagon‐like peptide‐1 (GLP‐1) and gastric inhibitory polypeptide (GIP) are
important insulinotropic hormones that enhance the insulin secretory response to feeding …

A group of neurons in the caudal nucleus of the solitary tract (NTS) processes
preproglucagon to glucagon-like peptides (GLP)-1 and-2, peptides that inhibit food intake …

Glucagon-like peptide 1 (GLP-1) was discovered as an insulinotropic gut hormone,
suggesting a physiological role as an incretin hormone, ie, being responsible, in part, for the …

The aim of the study was to investigate the effects of a dipeptidyl peptidase‐4 (DPP‐4)
inhibitor, of metformin, and of the combination of the two agents, on incretin hormone …

The prevalence of obesity and type 2 diabetes (T2D) is increasing worldwide, and these two
metabolic disorders are closely linked. Lifestyle modification, including weight loss and …